IL18 and irritable bowel syndrome: As such, therapeutic strategies to alter IL-18 bioactivity need to be carefully addressed to determine the appropriate dose (low vs. high) and most beneficial time (early vs. late) to neutralize endogenously produced IL-18 during chronic inflammatory diseases, including IBD (Figure 3).